

## HOUSE OF REPRESENTATIVES

NINETIETH SESSION

H. F. No. 1832

03/01/2017 Authored by Kiel  
The bill was read for the first time and referred to the Committee on Commerce and Regulatory Reform  
03/15/2017 Adoption of Report: Placed on the General Register  
Read for the Second Time  
05/01/2017 Referred to the Chief Clerk for Comparison with S. F. No. 1627  
05/04/2017 Postponed Indefinitely

- 1.1 A bill for an act
- 1.2 relating to health; requiring health plans to indicate level of coverage for certain
- 1.3 anticancer medication; amending Minnesota Statutes 2016, section 62A.3075.
- 1.4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
- 1.5 Section 1. Minnesota Statutes 2016, section 62A.3075, is amended to read:
- 1.6 **62A.3075 CANCER CHEMOTHERAPY TREATMENT COVERAGE.**
- 1.7 (a) A health plan company that provides coverage under a health plan for cancer
- 1.8 chemotherapy treatment shall not require a higher co-payment, deductible, or coinsurance
- 1.9 amount for a prescribed, orally administered anticancer medication that is used to kill or
- 1.10 slow the growth of cancerous cells than what the health plan requires for an intravenously
- 1.11 administered or injected cancer medication that is provided, regardless of formulation or
- 1.12 benefit category determination by the health plan company.
- 1.13 (b) A health plan company must not achieve compliance with this section by imposing
- 1.14 an increase in co-payment, deductible, or coinsurance amount for an intravenously
- 1.15 administered or injected cancer chemotherapy agent covered under the health plan.
- 1.16 (c) Nothing in this section shall be interpreted to prohibit a health plan company from
- 1.17 requiring prior authorization or imposing other appropriate utilization controls in approving
- 1.18 coverage for any chemotherapy.
- 1.19 (d) A plan offered by the commissioner of management and budget under section 43A.23
- 1.20 is deemed to be at parity and in compliance with this section.
- 1.21 (e) A health plan company is in compliance with this section if it does not include orally
- 1.22 administered anticancer medication in the fourth tier of its pharmacy benefit.

2.1 (f) A health plan company that provides coverage under a health plan for cancer  
2.2 chemotherapy treatment must indicate the level of coverage for orally administered anticancer  
2.3 medication within its pharmacy benefit filing with the commissioner.

2.4 **EFFECTIVE DATE.** This section is effective January 1, 2018, and applies to health  
2.5 plans offered, sold, issued, or renewed on or after that date.